Attovia Therapeutics (ATTO) insider Redmile converts 782,854 preferred shares and buys 600,000 in IPO

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported insider activity by investment entities associated with Redmile Group and Jeremy Green as ten percent owners. On August 6, 2026, 782,854 shares of Series B Preferred Stock automatically converted in full into the same number of common shares upon completion of Attovia’s IPO for no consideration. On the same date, Redmile-managed vehicles purchased an additional 600,000 shares of common stock at $17.00 per share in the IPO, including a 200,000-share direct purchase that brought one reported direct common position to 982,854 shares. The filing notes that Redmile and Jeremy Green may be deemed beneficial owners through their roles as manager and principal, while disclaiming beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

Net Buyer: 1,382,854 shares

Net Buy 4 txns

Insider Redmile Group, LLC, Green Jeremy, Redmile Biopharma Investments III, L.P.

Role 10% Owner | 10% Owner | 10% Owner

Bought 600,000 shs ($10.20M)

Type	Security	Shares	Price	Value
Conversion	Series B Preferred Stock F1, F2, F4	782,854	--	--
Conversion	Common Stock F1, F2, F4	782,854	--	--
Purchase	Common Stock F2, F4	200,000	$17.00	$3.40M
Purchase	Common Stock F3, F4	400,000	$17.00	$6.80M

Holdings After Transaction: Series B Preferred Stock — 0 shares (Indirect, See footnotes); Common Stock — 982,854 shares (Direct); Common Stock — 1,182,854 shares (Indirect, See footnotes)

Footnotes (4)

1. F1. On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering ("IPO"), for no consideration. The Series B Preferred Stock had no expiration date.
2. F2. These securities are held directly by Redmile Biopharma Investments III, L.P. ("RBI III"), which is managed by Redmile Group, LLC ("Redmile"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
3. F3. These securities were purchased in the IPO by certain private investment vehicles managed by Redmile (collectively, the "Redmile Clients"), and include the number of securities purchased by RBI III in the IPO reported in the line above.
4. F4. Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Key Figures

Series B Preferred Converted: 782,854 shares Common Shares Received on Conversion: 782,854 shares Direct Common Stock Purchase: 200,000 shares +3 more

6 metrics

Series B Preferred Converted 782,854 shares Automatically converted into common stock upon Attovia’s IPO on August 6, 2026

Common Shares Received on Conversion 782,854 shares Common stock issued in exchange for Series B Preferred at IPO, for no consideration

Direct Common Stock Purchase 200,000 shares Purchased at $17.0000 per share, held directly, on August 6, 2026

Indirect Common Stock Purchase 400,000 shares Purchased at $17.0000 per share by Redmile-managed vehicles on August 6, 2026

IPO Purchase Price $17.0000 per share Price paid for common stock purchases by Redmile-managed entities in the IPO

Direct Common Shares After Purchase 982,854 shares Direct common stock position reported after 200,000-share purchase on August 6, 2026

Key Terms

Series B Preferred Stock, initial public offering, beneficial ownership, pecuniary interest, +1 more

5 terms

Series B Preferred Stock financial

"On August 6, 2026, the Series B Preferred Stock converted by its terms"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

initial public offering financial

"automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

beneficial ownership financial

"RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein"

ten percent owner financial

"listed as a ten percent owner in the reporting persons section"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/08/2026 - 02:11 PM Accepted by SEC EDGAR 08/07/2026 - 09:47 PM Learn about SEC filing dates

FAQ

What insider transactions did Attovia Therapeutics (ATTO) report on August 6, 2026?

Attovia reported that Redmile-managed entities converted 782,854 shares of Series B Preferred Stock into common stock and purchased 600,000 common shares at $17.00 per share in connection with Attovia’s IPO.

How many Attovia (ATTO) Series B Preferred shares were converted and on what terms?

Redmile-affiliated holders saw 782,854 Series B Preferred shares automatically convert into 782,854 common shares on August 6, 2026 upon Attovia’s IPO, for no consideration, and the preferred stock had no expiration date.

What common stock did Redmile-related entities acquire in Attovia (ATTO) at $17 per share?

Redmile-managed vehicles purchased 600,000 common shares of Attovia at $17.00 per share in the IPO, including a 200,000-share direct purchase and another 400,000 shares held indirectly by certain Redmile-managed investment vehicles.

What was the reported Attovia (ATTO) common stock holding after the 200,000-share purchase?

After the 200,000-share direct common stock purchase at $17.00, one reported position showed 982,854 common shares held directly, reflecting holdings as of August 6, 2026 for that reporting line.

How are Redmile Group and Jeremy Green related to the Attovia (ATTO) securities?

The securities are held by Redmile-managed vehicles, including RBI III. Redmile, as investment manager, and Jeremy Green, as its principal, may be deemed beneficial owners but disclaim ownership beyond their pecuniary interests.

Were the Attovia (ATTO) insider purchases made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked as using such a plan, and the footnotes describe IPO-related purchases by Redmile-managed investment vehicles rather than pre-arranged trading plan activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Redmile Group, LLC

(Last) (First) (Middle)

900 LARKSPUR LANDING CIRCLE, SUITE 270

(Street)

LARKSPUR CALIFORNIA 94939

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		C		782,854	A	(1)	782,854	I	See footnotes(2)(4)
Common Stock	08/06/2026		P		200,000	A	$17	982,854	D(2)(4)
Common Stock	08/06/2026		P		400,000	A	$17	1,182,854	I	See footnotes(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(1)	08/06/2026		C			782,854	(1)	(1)	Common Stock	782,854	(1)	0	I	See footnotes(2)(4)

1. Name and Address of Reporting Person^*

Redmile Group, LLC

(Last) (First) (Middle)

900 LARKSPUR LANDING CIRCLE, SUITE 270

(Street)

LARKSPUR CALIFORNIA 94939

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Green Jeremy

(Last) (First) (Middle)

C/O REDMILE GROUP, LLC (NY OFFICE)

45 W. 27TH STREET, FLOOR 11

(Street)

NEW YORK NEW YORK 10001

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Redmile Biopharma Investments III, L.P.

(Last) (First) (Middle)

C/O REDMILE GROUP, LLC

900 LARKSPUR LANDING CIRCLE, SUITE 270

(Street)

LARKSPUR CALIFORNIA 94939

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. On August 6, 2026, the Series B Preferred Stock converted by its terms in full automatically into shares of the Issuer's common stock, upon the consummation of the Issuer's initial public offering ("IPO"), for no consideration. The Series B Preferred Stock had no expiration date.

2. These securities are held directly by Redmile Biopharma Investments III, L.P. ("RBI III"), which is managed by Redmile Group, LLC ("Redmile"). RBI III disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that RBI III is the beneficial owner of the reported securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

3. These securities were purchased in the IPO by certain private investment vehicles managed by Redmile (collectively, the "Redmile Clients"), and include the number of securities purchased by RBI III in the IPO reported in the line above.

4. Redmile may be deemed to beneficially own the reported securities as the investment manager of RBI III and the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

	By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC	08/07/2026
	/s/ Jeremy Green	08/07/2026
	By: /s/ Jeremy Green, Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)